THE ROLE OF LIQUID BIOPSY IN THE DIAGNOSIS OF GLIOBLASTOMA PROGRESSION

A.I. Ryabova¹, V.A. Novikov¹,², E.L. Choynzonov¹,², L.V. Spirina¹,², N.V. Yunusova¹,², A.A. Ponomareva¹, S.N. Tamkovich³,⁴, O.V. Gribova¹

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk, Russia¹
5, Kooperativnaya Street, 634009, Tomsk, Russia. E-mail: Bochkarevanv@oncology.tomsk.ru
Siberian State Medical University of the Ministry of Health of Russia, Tomsk, Russia²
2, Moskovsky Tract, 634050, Tomsk, Russia²
Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine,
Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia³
8, Academician Lavrentiev Ave., 630090, Novosibirsk, Russia³
Department of Clinical Biochemistry, Novosibirsk State University, Novosibirsk, Russia⁴
2, Pirogova St., 630090, Novosibirsk, Russia⁴

Abstract

Purpose: to summarize available data on the diagnostic value of various circulating biomarkers for the detection of glioblastoma recurrence. Material and Methods. A literature search was conducted using PubMed, ExoCarta and SILVA databases. Results. Glioblastoma multiforme (GBM) is the most common glioma in adults with an unfavorable prognosis. Treatment of tumor recurrence can improve the survival of patients. Neuroimaging is the standard method of diagnosing brain tumor recurrence. However, a neuroimaging method to clearly distinguish between pseudo-progression and tumor progression has not been found to date. Current molecular tumor profiling relies heavily on tissue resection or biopsy. Tissue profiling has several disadvantages in the central nervous system's tumors, including the challenge associated with invasive biopsy, the heterogeneous nature of many malignancies where a small biopsy can underrepresent the mutational profile. Liquid biopsy is a promising method in diagnosing malignant tumors. Blood collection is a simple, minimally invasive procedure, but cerebrospinal fluid allows tumor markers to be detected more confidently. However, collection of cerebrospinal fluid is a complex and invasive procedure that can be accompanied by serious complications. Conclusion. Biological fluid markers such as circulating tumor cells, extracellular vesicles, cell-free DNA and cell-free RNA allow for the detection of GBM, determination of molecular genetic features of cancer during response to therapy, and early detection of GBM recurrence.

Key words: extracellular vesicles, cell-free DNA, cell-free RNA, circulating tumor cells, glioblastoma recurrence, tumor diagnostics

Юнусова Наталья Валерьевна, Bochkarevanv@oncology.tomsk.ru

DOI: 10.21294/1814-4861-2022-21-3-104-116
УДК: 616-006.484.04-036.17-076
РОЛЬ ЖИДКОСТНОЙ БИОПСИИ В ДИАГНОСТИКЕ ПРОГРЕССИРОВАНИЯ ГЛИОБЛАСТОМЫ

А.И. Рябова1, В. А. Новиков1, Е. Л. Чойнзонов1, Л. В. Спирина1, Н. В. Юнусова1, А. А. Пономарева1, С. Н. Тамкович3, О. В. Грибова1

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, Томск, Россия1

Россия, 634009, г. Томск, пер. Кооперативный, 5. E-mail: Bochkarevanv@oncology.tomsk.ru1

ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России, Томск, Россия2

Россия, 634050, г. Томск, Московский тракт, 22

Лаборатория молекулярной медицины Института химической биологии и фундаментальной медицины СО РАН, Новосибирск, Россия3

Россия, 630090, г. Новосибирск, пр. Академика Лаврентьева, 8

Кафедра клинической биохимии, ФГБОУ ВО «Новосибирский национальный исследовательский государственный университет», Новосибирск, Россия4

Россия, 630090, г. Новосибирск, ул. Пирогова, 2

Аннотация

Цель исследования – обобщение имеющихся данных о диагностической ценности различных циркулирующих биомаркеров для диагностики рецидива глиобластомы. Материал и методы. Проведен биоинформатический поиск в универсальной базе данных pubmed, в базе данных экзосомальных белков, РНК и липидов ExoCarta, в базе данных внеклеточной ДНК, в базе данных внеклеточной ДНК silVa. Результаты. Мультиформная глиобластома (МГБ) – наиболее распространенная глиальная опухоль у взрослых с плачевным прогнозом. Лечение рецидива опухоли может улучшить выживаемость пациентов. Нейровизуализация – стандартный метод диагностики рецидива опухоли головного мозга. Однако методы нейровизуализации, позволяющие четко различать прогрессирование опухоли и связанные с лечением рентгенографические изменения на ранних стадиях, сегодня не найдены. Современное молекулярное профилирование опухоли в значительной степени зависит от резекции ткани или биопсии. Профилирование ткани имеет несколько недостатков при опухолях центральной нервной системы, в т. ч. проблемы, связанные с инвазивной биопсией, неоднородной природой многих злокачественных новообразований, когда небольшая биопсия может недооценивать мутационный профиль. Жидкая биопсия – перспективное направление современной онкологии. Сбор крови – это простая, малоинвазивная процедура, но спинномозговая жидкость позволяет более уверенно обнаруживать опухолевые маркеры, однако получение ее является сложной и инвазивной процедурой, которая может сопровождаться серьезными осложнениями. Заключение. Маркеры биологических жидкостей, такие как циркулирующие опухолевые клетки, внеклеточные везикулы, внеклеточная ДНК и внеклеточная РНК, позволяют выявить МГБ, определить молекулярно-генетические особенности рака во время ответа на терапию и обнаружить рецидив МГБ на ранней стадии.

Ключевые слова: внеклеточные везикулы, внеклеточная ДНК, внеклеточная РНК, циркулирующие опухолевые клетки, рецидив глиобластомы, диагностика опухолей.

Introduction

Glioblastoma multiforme (GBM) is the most frequently diagnosed and aggressive glial brain tumor. It is characterized by rapid progression and poor prognosis. According to the results of the Central Brain Tumor Registry of the United States, the largest population register of tumors of the central nervous system, the overall one-year survival of patients with GBM is about 40 %, and the five-year survival is 5–7 % [1]. Even with the current standard of combined treatment in significant randomized Phase III trials, the median progression-free survival does not exceed 11 months. The overall survival is less than two years [2–4]. Currently, the definite diagnosis is established on histological examination of the biopsy samples. How well a tumor will respond to treatment, remain in remission, or recur after treatment depends on the specific tumor type and its molecular makeup [5]. The significant advances in brain imaging have resulted in more detailed anatomic and functional localization of gliomas concerning the eloquent cortex and improvements in microsurgical techniques, and enhanced adjuvant stereotactic radiation delivery. But a recurrent tumor remains a huge issue in modern oncology [6].

The adequate treatment of recurrent GBM can prolong patients’ survival and improve their quality of life [7]. Contrast-enhanced magnetic resonance imaging (MRI), widely used during GBM patients’ follow-up, has no 100 % sensitivity and specificity. A contrast accumulation in the brain during MRI after radiation...
therapy may indicate the recurrent tumor and the phenomenon of "pseudoprogression" or radiation-induced necrosis. Pseudoprogression occurs in 10–30 % of patients with GBM, usually during the first 12 weeks after adjuvant chemoradiotherapy (CRT) [8]. The opposite phenomenon, namely "pseudo-response", is characterized by a rapid decrease in contrast enhancement accumulation and stabilization of the blood-brain barrier under the influence of antiangiogenic therapy. It does not indicate an exact tumor response to treatment [8, 9]. Perfusion MRI and nuclear medicine techniques can distinguish between the actively growing tumor and post-radiation necrosis [10]; however, these techniques are not available in all clinics and cannot always detect a recurrent tumor in the early stages [11, 12]. Biopsy verification of GBM recurrence is not performed due to the highly invasive nature of the procedure and complications that may worsen the patient’s condition. When it is impossible to distinguish pseudo-progression from GBM progression, treatment decisions are usually delayed until imaging techniques clarify tumor behavior [13]. Delayed treatment often leads to tumor growth, an increase in the neurological deficit, and poor prognosis.

DNA-based GBM markers include IDH1, IDH2, MGMT, EGFR mutations and 1p/19q co-deletion [14]. Besides, GBM secrete specific tumor markers (soluble proteins, circulating nucleic acids) both independently and as part of circulating tumor cells (CTCs) and extracellular vesicles (EVs) into the cerebrospinal fluid (CSF). Then these biomarkers can cross the intact blood-brain barrier [15, 16], and it is possible to detect them in the blood of GBM patients. By this reason the potential of the so-called "liquid biopsy" in the diagnosis and treatment of glial tumors, including GBM, is being actively investigated [17–19]. The advantage of liquid biopsy is that it reflects the entire tumor’s genetic diversity and allows repeated studies without the risk of serious complications. The main circulating biomarkers found in biological fluids in GBM patients are CTCs, EVs, circulating coding and non-coding nucleic acids. Currently, GBM does not have a reliable biomarker in serum or CSF. There is no agreed guidance on using single or multiple GBM biomarkers assessments in a clinical setting [19–21]. Accordingly, literature data were analyzed regarding the role of CTCs, EVs, and cell-free nucleic acids secreted into the CSF and blood in the diagnosis of recurrent glioblastoma.

Circulating tumor cells

The importance of detecting of CTCs in CSF and peripheral blood to assess tumor progression and response to therapy has been shown in numerous studies in malignant tumors of various localizations [22–24]. Since extracranial metastases are observed only in 0.2-0.5 % of GBM patients [25, 26], for a long time, it was believed that a unique microenvironment in the brain prevented the migration of glioma cells into the bloodstream [26]. The first attempt to detect CTCs in blood using real time quantitative reverse transcription polymerase chain reaction assay for the detection of mRNA encoding glial fibrillary acidic protein (GFAP) in GBM patients was unsuccessful [27]. The following attempts were made only a decade later. In 2014, in several studies, tumor cells were found in the peripheral blood of GBM patients. Müller and colleagues (2014) isolated CTCs from blood in GBM patients using a fluorescence immunocytochemical analysis with an anti-GFAP antibody as a putative marker for CTCs of glioblastoma. Only 29 out of 141 (20.6 %) patients were found to have 1 to 22 GFAP-positive cells that contained GBM-associated genomic aberrations [25].

For CTCs detection in blood, Sullivan et al. (2014) used CTC isolation protocol with staining with a combination of antibodies to CD14, CD16, CD45, and nuclear staining with DAPI. The number of CTCs detected in 12 patients with a progressive brain tumor was higher (median 11.8 cells per ml) than in 21 patients with stable disease (median 2.1 cells per ml) (p<0.001). Single CTCs isolated from GBM patients demonstrated enrichment for mesenchymal over neural differentiation markers compared with primary GBMs [28].

MacArthur et al. (2014) developed a CTC detection method in the blood samples of GBM patients using an adenoviral-based probe to telomerase reverse transcriptase. The CTC status was confirmed by a FISH study of GFAP and nestin expressions, epidermal growth factor receptor (EGFR) amplification, and the absence of epithelial cell adhesion marker. CTCs were detected in 8 out of 11 (72.7 %) patients with high-grade glioma before starting radiation therapy; the average value was 8.8 cells in ml of blood. The CTC’s diagnostic significance for the early differential diagnosis of progression and pseudoprogression was shown in two cases [11].

Gao et al. (2016) used the determination of chromosome 8 aneuploidy using CEP8-FISH method to detect CTCs. The study included 31 patients with primary WHO grade II-IV gliomas including 11 patients with glioblastoma. The incidence of CTCs in the peripheral blood of patients with grade II–IV glioma was 83 %, 63 %, and 82 %, respectively, with no statistically significant differences (p=0.525). All detected CTCs showed five or more copies of chromosome 8, with the number of CTCs varied from 1 to 10 per 7.5 ml of blood. In five patients with a new growing lesion on the first MRI scan after radiation therapy, the possibility of determining the quantity of CTCs in the peripheral blood for early differential diagnosis of a tumor and radiation necrosis was confirmed [12].

The detection of CTCs is a promising approach to the GMB diagnosis since reliable gliomas markers have not yet been established. The use of various techniques made it possible to isolate CTCs from the blood of GBM patients in 82 % of cases. A clear relationship
miRNA expression levels as biomarkers of treatment response in GBM patients
Уровни экспрессии микроРНК как биомаркеры ответа на лечение у пациентов с глиобластомой

<table>
<thead>
<tr>
<th>miRNAs</th>
<th>Sample information/Информация об образцах</th>
<th>Treatment modality/Лечение</th>
<th>Level after treatment/Уровень маркера после лечения</th>
<th>References/Ссылки</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-10b, miR-21</td>
<td>CSF, 19 GBM patients/ЦСЖ 19 больных ГБ</td>
<td>Remission vs progression/Ремиссия vs прогрессия</td>
<td>Decrease in remission/Снижение при ремиссии</td>
<td>Teplyuk N.M. et al., 2012 [93]</td>
</tr>
<tr>
<td>miR-21</td>
<td>Plasma, 10 GBM patients/Плазма 10 больных ГБ</td>
<td>Chemoradiation/Химиорадиотерапия</td>
<td>Decrease/Снижение</td>
<td>Wang Q. et al., 2012 [92]</td>
</tr>
<tr>
<td>miR-128, miR-342-3p</td>
<td>Plasma, 10 GBM patients/Плазма 10 больных ГБ</td>
<td>Surgery; Chemoradiation/Хирургия, химиорадиотерапия</td>
<td>Increase/Повышение</td>
<td>Wang Q. et al., 2012 [92]</td>
</tr>
<tr>
<td>miR-15b, miR-23a, miR-133a, miR-150, miR-497, miR-548b-5p</td>
<td>Serum, 26 GBM patients/Сыворотка 26 больных ГБ</td>
<td>Surgery/Хирургия</td>
<td>Increase/Повышение</td>
<td>Yang C. et al., 2013 [109]</td>
</tr>
<tr>
<td>miR-454-3p</td>
<td>Plasma, 22 GBM patients/Плазма 22 больных ГБ</td>
<td>Surgery/Хирургия</td>
<td>Decrease/Снижение</td>
<td>Shao N. et al., 2015 [110]</td>
</tr>
<tr>
<td>miR-128</td>
<td>Serum, 59 glioma patients/Сыворотка 59 больных с глиомами</td>
<td>Surgery/Хирургия</td>
<td>Increase/Повышение</td>
<td>Sun J. et al., 2015 [111]</td>
</tr>
<tr>
<td>miR-185</td>
<td>Plasma, 19 GBM patients/Плазма 19 больных ГБ</td>
<td>Chemoradiation/Химиорадиотерапия</td>
<td>Decrease/Снижение</td>
<td>Tang H. et al., 2015 [112]</td>
</tr>
<tr>
<td>miR-205</td>
<td>Serum, 10 glioma patients/Сыворотка 10 больных с глиомами</td>
<td>Surgery/Хирургия</td>
<td>Increase/Повышение</td>
<td>Yue X. et al., 2016 [108]</td>
</tr>
<tr>
<td>miR-26a</td>
<td>Serum, 15 GBM patients/Сыворотка 15 больных ГБ</td>
<td>Surgery/Хирургия</td>
<td>Decrease/Снижение</td>
<td>Parviz H.M. et al., 2019 [113]</td>
</tr>
<tr>
<td>miR-214</td>
<td>Serum, 30 glioma patients/Сыворотка 30 больных с глиомами</td>
<td>Surgery/Хирургия</td>
<td>Decrease/Снижение</td>
<td>Wang J. et al., 2019 [114]</td>
</tr>
</tbody>
</table>

Note: CSF – cerebrospinal fluid, GB – glioblastoma.

between the number of CTCs and tumor progression/pseudoprogression has been shown [17, 18, 25, 28]. However, the quantity of studies is limited, the quantity of patient samples are not representative, and different CTCs isolation approaches make it difficult to compare the results. There are several limitations to the widespread use of CTCs as a biomarker for glioblastoma progression: 1) the detection of GBM CTCs in the peripheral blood requires a complex combination of technologies and relatively immediate blood sample processing; 2) the method with optimal sensitivity and specificity has not been determined yet. The frequency of CTCs released into the peripheral blood from GBM has not been established.

A major advantage of the next generation sequencing approach for detecting CTCs is the simultaneous identification of several markers relevant for GBM diagnostics, allowing molecular diagnostics on cytological specimens [29].

Extracellular vesicles
EVs are extracellular structures enclosed in a lipid bilayer, secreted or released by normal and tumor cells. EVs can be divided into exosomes, microvesicles, and apoptotic bodies based on the size, morphology, and biogenesis mechanism [30]. EVs released by GBM cells contain a wide range of molecules, including nucleic acids and proteins, which correspond to the primary tumor cells’ specific molecular features and are changed during treatment [21, 31, 32]. Simultaneously, the lipid membrane protects the EVs’ internal contents from enzymatic degradation [30, 33]. It has been shown that EVs from tumor cells cross intact blood-brain barrier and can be found in the blood of GBM patients [16]. EVs can be isolated from CSF and blood plasma by ultracentrifugation, ultrafiltration, or immunoprecipitation. Transmission electron microscopy, nanoparticle tracking analysis, flow cytometry, or western blotting are usually performed to confirm the EVs nature [34, 35].
EVs produced by GBM tumors have been shown to play an essential role in cellular communication and modulation of the tumor microenvironment. They provide tumor heterogeneity, modulate proliferation, reprogram metabolic activity, induce angiogenesis and invasion, and contribute to suppression of the immune response and acquisition of drug resistance [36, 37]. As GBM-derived EVs contain specific “molecular signatures” of their parental cells and can transmigrate across the blood-brain barrier, they are considered a valuable source of potential diagnostic biomarkers.

Several studies have noted a significant increase in the EVs in GBM patients’ blood than people with other malignant neoplasms of the central nervous system and healthy ones [38, 39], however, no correlation was found between the EVs level and the patient’s overall survival [40]. Koch et al. (2014) examined serum microvesicles’ levels in 11 patients with GBM. Samples were collected before CRT, and 1, 3, 6, 12, and 24 months after CRT. A statistically significant difference in the number of microvesicles in tumor progression cases was found compared to patients who responded to treatment (p=0.014) [41]. Andre-Gregoire et al. (2018) isolated exosomes from plasma of six patients with newly diagnosed GBM and healthy donors. Isolated EVs in both groups of patients had a comparable average diameter of 80 nm. However, the exosomes concentration in patients’ plasma with GBM was higher than in the control group [38].

Osti et al. (2019) examined patients with GBM (n=43), healthy people (n=33), and patients with other central nervous system malignancies (n=25). Plasma samples were purified by differential centrifugation with ultrafiltration through a 0.22 μm filter. The average size of EVs in GBM patients and the validation group was about 150 nm. The number of circulating EVs was significantly higher in GBM patients than in healthy controls and patients with metastatic and extra-brain tumors. It has been shown that the EVs level increased in preoperative plasma samples, reliably decreases after the resection of the primary tumor, and again increases with the tumor relapse (p=0.028) [39].

As previously shown by J.M. Figueroa et al (2017) CSF-derived EVs contain RNA signatures reflective of the underlying molecular genetic status of GBMs in terms of wtEGFR expression and EGFRvIII status. The high specificity (up to 98%) of the CSF-derived EV diagnostic test gives us an accurate determination of positive EGFRvIII tumor status which can be useful for therapy strategy [21]. Shao et al. (2012) analyzed a panel of four GBM-related proteins (EGFR, EGFRvIII, podoplanin (PDPN), and isocitrate dehydrogenase 1 (IDH1)) in EVs obtained from the serum of 12 glioblastoma patients. It was shown that EVs demonstrate a distinct molecular signature of the tumor, and increased expression of EGFR, EGFRvIII, PDPN, and IDH1 R132H made it possible to diagnose GBM with an accuracy of 36% to 76% using separate markers. When the results were combined, the accuracy increased to 91%. The drug response index calculated based on the relative changes in the amount of GBM EVs, and the expression levels of EVs biomarkers before and after CRT made it possible to reliably differentiate patients with progression from those who responded to therapy (p<0.005) [42].

Currently, vesicular miRNAs are the most attractive for differential diagnosis, diagnosis of glioblastoma recurrence and assessment of the effectiveness of its therapy. The study of miRNAs obtained from EVs showed the possibility of distinguishing of GBM from non-oncologic patients based on the increased content of miR-21 in CSF EVs with high sensitivity and specificity (87% and 93%, respectively) [43]. Ebrahimkhani et al. found twenty-six microRNAs, differentially expressed in GBM patient exosomes. Combination of just four miRNAs (miR-182-5p, miR-328-3p, miR-485-3p, miR-486-5p) distinguished GBM patients from healthy controls with 100% accuracy [44]. A recent meta-analysis found 24 EVs derived RNA biomarkers for GBM diagnosis, and the overall sensitivity and specificity of 16 ones in the meta-analysis were 76% and 80%, respectively [45]. Santangelo et al. (2018) evaluated the expression levels of blood-derived exosomal miR-21, miR-222, and miR-124-3p from 25 patients with high-grade gliomas before and after surgery. The assessment of these miRNAs expression in samples obtained after surgery showed a sharp decrease in the number of individual miRNAs: miR-21 (p<0.001), miR-222 (p<0.01), and miR-124-3p (p<0.01), as well as in the cumulative expression level of the studied miRNAs (p<0.001) [46]. Lan et al. (2018) investigated the exosomal miR-301a in the serum of 7 patients with GBM before surgery, two weeks after surgery, and during tumor progression. It was found that its level was significantly higher in patients with glioma than in healthy controls and patients with non-glial tumors (p<0.01). The blood-derived miR-301a expression was decreased considerably after surgery (p<0.01) and again increased in the GBM recurrence (p<0.01) [47]. In the next study, the exosomal miR-210 level was studied in 10 patients with GBM. Blood samples were taken before the primary tumor’s surgical treatment, after surgery, and after diagnosis of disease recurrence. The miR-210 level was significantly reduced after surgery (p<0.01) and at the time of the GBM recurrence (p<0.01) [48].

The expediency of detecting various subpopulations of blood plasma exosomes for evaluating the effectiveness of immunotherapy in patients with recurrent forms of glioblastomas after standard therapy has been shown. Galbo et al. (2017) evaluated the level of blood serum exosomes expressing CD9, GFAP, and survivin on their surface in 8 patients with recurrent malignant gliomas during anti-survivin immunotherapy [49]. Survivin is a family member of apoptosis protein inhibitors associated with poor prognosis and
was a statistically significant increase in the CD9+/survivin+ exosomes proportion in patients with glioma including gliomas [50]. It was shown that the CD9+/survivin+ exosomes proportion in patients with glioma was 9.1% and only 0.43% in the control group. There was a statistically significant increase in the CD9+/survivin+ exosomes level (p=0.0299) and CD9+/GFAP+ survivin+ exosomes (p=0.0225) in glioma progression. The authors suggested that the CD9, survivin, and GFAP combined detection on exosomes’ surface could be used to assess tumor response in patients receiving survivin-based immunotherapy and to monitor glioma progression. Wang et al. (2019) compared the EGFR expression in serum EVs of 23 patients with glioma before and one week after surgery. Most GBM is characterized by the EGFR1 overexpression; therefore, an EGFR serum level analysis appears to be a promising biomarker [33].

The disadvantages of using EVs as diagnostic material include the duration of vesicles isolation and the presence of a large volume of CSF and blood. There is a problem of isolating the total pool and the pool of tumor EVs, since the concentration of a specific marker of gliomas GFAP on vesicles will be several hundred times lower than on cells of the original tumor due to the peculiarities of exosome biogenesis [30, 51]. There also remains the dilemma of using CSF or blood as a source of total EV or individual EV fractions for the early diagnosis of glioblastoma recurrence, as predictor and prognostic biomarkers.

Cell-free DNA

Extracellular nucleic acids (cDNAs) circulate in the blood as a part of supramolecular complexes, such as nucleosomes, complexes with proteins and lipoproteins, and can be bound to the surface of blood cells [52]. Sources of cell-free DNA (cfDNA) are apoptosis, necrosis and active secretion by cells [53]. cfDNA seems to be a promising real-time tumor load biomarker, which can provide minimally invasive monitoring of the response to anti-tumor therapy [54].

Recent studies have confirmed the feasibility of using cfDNA quantification as a biomarker for GBM progression. In a prospective study, Nørøxe et al. (2019) evaluated blood samples from newly diagnosed GBM patients from the date of diagnosis or the start of treatment until disease progression. They observed the highest cfDNA values before surgical procedure and during tumor progression. Determining the cfDNA level helped to differentiate actual tumor progression from pseudoprogression in 3 cases [55].

In another single-center pilot study, Bagley et al. (2020) evaluated plasma cfDNA levels in 42 patients with newly diagnosed GBM from the date of diagnosis until disease progression. Before treatment, patients with GBM had a higher plasma cfDNA concentration than healthy patients in the control group (average 13.4 vs 6.7 ng/ml, p<0.001). A significant increase in plasma cfDNA was found during disease progression in most patients [54]. Thus, the level of cfDNA in peripheral blood can be a valid biomarker of disease progression.

Since an increase of concentration of ctDNA is not specific disease marker (cfDNA high level in the blood was also described in patients with autoimmune diseases [56], sepsis and systemic inflammatory response syndrome [57], myocardial infarction [58], ect., detection of tumor specific genetic alterations can significantly increase the method specificity.

The first attempts to determine tumor ctDNA in the blood of patients with GBM relied on the identification of prognostically significant genetic markers, such as methylation profiles of individual gene promoters, loss of heterozygosity of chromosome 10, IDH1 mutation, and EGFRvIII deletion [59–64]. Some studies have shown that tumor ctDNA can be isolated from the GBM patient’s blood in 15–88.8% of cases [54, 62, 65–71].

The possibility of detecting tumor DNA in the CSF of a patient with glioblastoma was first reported by Rhodes et al. in 1995 when they determined tumor-derived p53 DNA in cisternal CSF at autopsy using allele-specific PCR [72]. Wang et al. examined CSF collected during surgery in 11 patients with GBM. In all the cases, tumor bulk was adjacent to the CSF space (the subarachnoid area or the ventricular wall) and had detectable tumor DNA in CSF [70]. The ctDNA analysis in patients with gliomas allows determining the gene’s methylation status, predicting the patients’ response to therapy. The sensitivity and specificity are about 59 and 100%, respectively [62, 69]. The sensitivity in the detection of ctDNA in the CSF in GBM patients reaches 70% [69], and in cases of tumor node adherence it is 100% [70–71]. To test whether the amount of detectable mutant DNA in plasma can reflect the tumor’s state, the authors amplified the mutant DNA from these patients’ plasma. In two cases with total tumor resection, no ctDNA was detected in the blood plasma, while in one case, a residual amount of ctDNA was detected, reflecting incomplete tumor resection [64].

Further studies have focused on genome-wide tumor sequencing and the use of multi-gene panels to detect tumor ctDNA. The relationship between the ctDNA gene methylation and therapy response or tumor recurrence in the available literature is not described. There was no information about the disease stage, mutational profile of the tumor tissues, and its relationship to the blood gene status. In the study Bagley et al. (2019), at least one somatic mutation was detected in reoperative plasma samples from 11 of 20 (55%) patients with newly diagnosed GBM using next-generation sequencing (NGS). However, none of the plasma mutations were identified in the corresponding tumor samples [54]. Such results can be partially explained by the pronounced molecular heterogeneity of GBM, which is found even within a single tumor bulk [8]. The tremendous success in detecting tumor ctDNA in the blood of patients with
glioblastoma was achieved by Ahmed et al. (2019), which analyzed 27 patients with malignant gliomas using NGS and their specialized 50-gene panel. In 24 out of 27 (88.8 %) patients, ctDNA was detected. A good correlation was obtained between NGS results in plasma and PCR in tumor samples [68].

De Mattos-Arruda et al. compared the ratio of tumor ctDNA in plasma and CSF based on somatic genomic changes detected in tumors by exomic sequencing [73]. At least one tumor mutation was detected in CSF of 4 GBM patients, while in the blood plasma, the tests were negative. To assess the feasibility of using tumor ctDNA as a biomarker of disease progression, the frequency of mutant alleles in CSF and blood was determined in 2 patients using digital PCR during anti-tumor therapy. The tumor ctDNA level in CSF decreased with the response to systemic therapy and increased in disease progression. In a larger study using targeted analysis based on NGS, Miller et al. (2019) evaluated many diffuse gliomas, including 46 adult patients with GBM. Tumor DNA was detected in 59 % patients with glioblastoma. The tumor ctDNA presence in CSF was associated with tumor progression (p=0.0005), higher tumor burden (p=0.0000017), and tumor spread to the CSF space (p=0.02). Based on the results obtained, the authors suggested that tumor ctDNA in CSF may be an early indicator of glioma progression [74].

A low detection rate of tumor mutations in patients' peripheral blood makes it difficult to use tumor ctDNA as a biomarker of GBM progression. The study of CSF for tumor mutations seems more promising. However, lumbar puncture is not always possible to perform, as it is accompanied by some complications and the refusal of patients to participate in studies requiring lumbar puncture [75].

Cell-free RNAs
The cell-free RNA (ctRNA) secreted by glioblastoma cells could prove a valuable resource for biomarker discovery. Tumor-released ctRNA may be coding and non-coding. Non-coding RNA play an essential role in almost all tumor genesis, including tumor initiation, progression, therapy resistance, and can be found in the blood and CSF of patients with gliomas [18, 76–78].

To date, several studies confirming the diagnostic [79, 80], prognostic [81–85], and predictive role [86, 87] of circular RNA (circRNA) in patients with brain gliomas have been published. Despite the existing possibility of detecting circRNA in body fluids, the expression of circRNA was determined mainly in tumor tissue. The potential of circRNA in the non-invasive diagnosis of glioblastoma recurrence is currently unclear. The role of long non-coding RNAs (lncRNAs) as a biomarker has been studied somewhat more broadly. More and more studies suggest lncRNAs to be promising diagnostic biomarkers and therapeutic targets in many cancers, including gliomas. Understanding the role of lncRNAs in gliomas may lead to discovering the novel molecular mechanisms behind glioma biological features [88]. In particular, it was shown, that the high TP73-AS1 and MALAT1 predict poor prognosis in primary GBM cohorts and these lncRNAs promote tumor aggressiveness and temozolomide (TMZ) resistance in GBM cohorts [89, 90]. LncRNA may also be ideal for gene/protein delivery in future brain cancer therapies [91]. However, there is no information about the study of lncRNA levels in the blood or CSF of patients with GBM during the treatment course and follow-up in the available literature.

The plasma levels of miR-21, miR-128, and miR-342-3p were significantly altered in GBM patients compared to normal controls, that could discriminate glioma from healthy controls with high specificity and sensitivity [92]. MiR-10b and MiR-21 in the CSF are significantly increased in patients with GBM. Quantification of as few as seven microRNAs in CSF enables differential recognition of glioblastoma and metastatic brain cancer using computational machine learning tools with high accuracy (91–99 %) [93, 94]. The signature of microRNAs in serum, including miR-128, miR-342-3p, miR-194, miR-628-3p, allows distinguishing of blood samples from patients with GBM and healthy control groups (the accuracy, sensitivity, and specificity is 81 %, 79 %, and 81 %, respectively) [95, 96].

The relationship between miRNAs dysregulation and prognosis in patients with GBM was shown. The miRNA expression signature of 10 microRNAs in glioblastoma samples can predict GBM patient survival [97]. MiR-182, miR-20a-5p, miR-106a-5p and miR-222-3p high level and miR-182, miR-145-5p, and miR-485-3p decreased level in the GBM patients' blood are significantly associated with worse survival [98–100]. Many studies have evaluated surgery's effect and combined modality treatment on the miRNA levels in blood or CSF [76, 92, 101–112]. For example, miR-125b-2 and miR-223 play a role in tumor sensitivity to TMZ chemotherapy [101, 102], and miR-21, miR-128, miR-301a and miR-145-5p maintain the resistance to radiation therapy [103–106].

The diagnostic value of miRNA as a biomarker for glioblastoma recurrence has been shown only in a few studies on a small amount of clinical material [46, 48, 93]. Teplyuk et al. (2012) found the elevated miR-21 and miR-10b level in CSF in only 1 of 19 GBM patients. After chemoradiotherapy, the miR-21 level in CSF was comparable with that in the control (non-tumor) group, while the miR-10b level was significantly higher than in the control group. The sharp increase in the miR-21 level and a further increase in miR-10b level at a later date (25 weeks) indicated disease progression, confirmed by MRI, PET-CT, and repeated biopsy. In this case, no single miRNA behaved as a simple tumor burden biomarker [93]. Subsequently, significant variability in miRNA profiles

**SiBERIAN JOURNAL OF ONCOLOGY. 2022; 21(3): 104–116**
Fig. 1. Текущее состояние и перспективы жидкой биопсии при ГБМ.

Примечание: ВВ – внеклеточные везикулы; ЦОКи – циркулирующие опухолевые клетки; МРТ – магнитно-резонансная томография; ЦСЖ – спинномозговая жидкость

СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ. 2022; 21(3): 104–116
markers in the CSF and or blood of patients will make it possible to individualize the treatment of patients and timely monitor the effectiveness of antitumor therapy. Nevertheless, liquid biopsy still has a number of limitations for widespread use in practical medicine (Fig. 1). Therefore, a large number of studies are needed to test the efficacy and reliability of liquid biopsy in patients with GBM, and we need to continuously develop simpler and more accurate methods for monitoring biomarkers and evaluating efficacy. We believe that CSCs, EVs, ctDNA, and ctRNA in cerebrospinal fluid and or blood will have broad application prospects in the diagnosis, prognosis, and treatment response of patients with glioblastoma in the future.


Evgeny L. Choynzonov: revision for important intellectual content.
Lyudmila V. Spirina: preparation of manuscript.
Natalia V. Yunusova: preparation of manuscript, final approval of the version of the manuscript for publication.
Anastasiya A. Ponomaryova: preparation of manuscript.
Svetlana N. Tamkovich: revision for important intellectual content.
Olga V. Gribova: preparation of manuscript.

Funding
This study required no funding.

Conflict of interests
The authors declare that they have no conflict of interest.

СВЕДЕНИЯ ОБ АВТОРАХ


Юнусова Наталья Валерьевна, доктор медицинских наук, ведущий научный сотрудник, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; профессор кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России (Томск, Россия). E-mail: Bochkarevanv@oncology.tomsk.ru. SPIN-код: 3513-1888. Researcher ID (WOS): C-9275-2012. Author ID (Scopus): 8354141400. ORCID: 0000-0003-4595-4177.


Финансирование
Это исследование не потребовало дополнительного финансирования.

Конфликт интересов
Авторы заявляют об отсутствии конфликта интересов.